Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.

Eli Lilly announced on " Good Morning America " Monday that its GLP-1 weight-loss drug Zepbound will now be available in a ...

The company said the weight-loss drug will be available at the same self-pay price in either the single-dose vial format or ...

Novo Nordisk’s CagriSema has been outperformed by Eli Lilly’s Zepbound (tirzepatide) in a head-to-head obesity trial. The ...

The CagriSema study results are a setback for the Danish drugmaker in its efforts to regain ground lost to Eli Lilly in the ...

New trial data show tirzepatide outperforms a GLP 1 combo in weight loss, reshaping obesity drug competition, and treatment ...

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use ...

The failure of its next-generation obesity drug to match Eli Lilly's blockbuster has blown a hole in Novo's post-Ozempic ...

U.S. childhood and teen obesity rates have reached record-highs while adult obesity rates may be slowing, according to two ...

Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo ...

Judge Karen Marston of the Eastern District of Pennsylvania issued the Order on February 23, 2026 Appointing Jason Goldstein to Co-Chair of the Plaintiffs' Executive Committee and Federal-State Court ...